Booij J - Search Results

1

Evaluation of high-resolution pinhole SPECT using a small rotating animal.

Habraken JB, de Bruin K, Shehata M, Booij J, Bennink R, van Eck Smit BL, Busemann Sokole E. Habraken JB, et al. Among authors: booij j. J Nucl Med. 2001 Dec;42(12):1863-9. J Nucl Med. 2001. PMID: 11752086 Free article.

2

In vitro and in vivo characterization of newly developed iodinated 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]piperazine derivatives in rats: limited value as dopamine transporter SPECT ligands.

Rijks LJ, Booij J, Doornbos T, Boer GJ, Ronken E, de Bruin K, Vermeulen RJ, Janssen AG, Van Royen EA. Rijks LJ, et al. Among authors: booij j. Synapse. 1996 Jul;23(3):201-7. doi: 10.1002/(SICI)1098-2396(199607)23:3<201::AID-SYN9>3.0.CO;2-C. Synapse. 1996. PMID: 8807748

3

Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease.

Vermeulen RJ, Wolters EC, Tissingh G, Booij J, Janssen AG, Habraken J, Sokole-Busemann E, Stoof JC, Van Royen EA. Vermeulen RJ, et al. Among authors: booij j. Nucl Med Biol. 1995 Nov;22(8):985-91. doi: 10.1016/0969-8051(95)02020-9. Nucl Med Biol. 1995. PMID: 8998476 Clinical Trial.

4

Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease.

Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, van Royen EA. Booij J, et al. Eur J Nucl Med. 1997 Jan;24(1):68-71. doi: 10.1007/BF01728311. Eur J Nucl Med. 1997. PMID: 9044880

5

[123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, Wolters EC, van Royen EA. Booij J, et al. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):133-40. doi: 10.1136/jnnp.62.2.133. J Neurol Neurosurg Psychiatry. 1997. PMID: 9048712 Free PMC article. Clinical Trial.

6

IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism.

Tissingh G, Booij J, Winogrodzka A, van Royen EA, Wolters EC. Tissingh G, et al. Among authors: booij j. J Neural Transm Suppl. 1997;50:31-7. doi: 10.1007/978-3-7091-6842-4_4. J Neural Transm Suppl. 1997. PMID: 9120422 Review.

7

Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography.

Claus JJ, Dubois EA, Booij J, Habraken J, de Munck JC, van Herk M, Verbeeten B Jr, van Royen EA. Claus JJ, et al. Among authors: booij j. Eur J Nucl Med. 1997 Jun;24(6):602-8. doi: 10.1007/BF00841396. Eur J Nucl Med. 1997. PMID: 9169565

8

Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography.

Booij J, Korn P, Linszen DH, van Royen EA. Booij J, et al. Eur J Nucl Med. 1997 Jun;24(6):674-7. doi: 10.1007/BF00841408. Eur J Nucl Med. 1997. PMID: 9169577 Clinical Trial.

9

[123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls.

Tissingh G, Bergmans P, Booij J, Winogrodzka A, Stoof JC, Wolters EC, Van Royen EA. Tissingh G, et al. Among authors: booij j. Eur J Nucl Med. 1997 Sep;24(9):1171-4. doi: 10.1007/BF01254252. Eur J Nucl Med. 1997. PMID: 9283113

10

[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys.

Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, Janssen AG, Van Royen EA. Booij J, et al. Synapse. 1997 Nov;27(3):183-90. doi: 10.1002/(SICI)1098-2396(199711)27:3<183::AID-SYN4>3.0.CO;2-9. Synapse. 1997. PMID: 9329154

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page